For companies that go public, how do those that were backed primarily by angel investors fare against those primarily backed by venture capitalists? That was one of the questions addressed in a working paper recently published by two professors from the University of New Hampshire. They examined data related to the pre-initial public offering (IPO) shareholders of companies that subsequently went public. The conclusions from the study provide interesting information that should be considered for companies looking to go public as part of their long term capitalization plan.
Read more from the article by Matt Storms that was recently published by the Wisconsin Technology Network News.
How best to deal with neglected diseases?
In 2005, researchers coined the term "neglected tropical diseases" to refer to thirteen diseases primarily occurring in rural, poor areas that have been largely ignored by policymakers and public health officials. These diseases, including sleeping sickness, river blindness, hookworm infection and more, traditionally fall second in attention and funding to "the big three" -- HIV/AIDS, malaria, and tuberculosis. Steven S. Clark
Despite a recent increase in funding for NTDs from private and government sources, there is debate how best to use this money. Would it be more effective to focus on the socio-environmental roots of disease, such as sanitation, clean water, education, etc--or is it best to focus on developing new treatments? The problem with the former is that it is expensive and would take a very long time to accomplish world-wide. The problem with the latter is that drug treatment won't prevent later reworming of treated individuals.
Posted by Steven S. Clark, PhD on May 19, 2010 at 12:48 PM | Permalink | Comments (0) | TrackBack (0)
Technorati Tags: drugs, Neglected tropical diseases, NTDs, PLoS Medicine, socio-environmental, The Scientist
Digg This | Save to del.icio.us